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Objective:  To  establish  the relative  importance  of  Salmonella  enterica  serovar  Typhi  with  non-classical
quinolone  resistance.
Methods:  Eight  hundred  and  ninety-one  isolates  of  S. Typhi,  isolated  between  2004  and  2011,  were  tested
for antibiotic  susceptibility  determination  using  disc diffusion  and  E-test.  The  mechanisms  of ﬂuoro-
quinolone  resistance  were  studied  in  a sub-set  of  the  NALS (nalidixic  acid susceptible)  isolates  by wave
nucleic  acid  fragment  analysis  of  PCR products  from  gyrA,  gyrB,  parC  and  parE and  from  the  plasmid
borne  determinants:  qnrA,B,S;  aac(6′)-Ib-cr  and qepA.  To  assess  genetic  relatedness  multi-locus  variable
number  tandem  repeat  analysis  was  carried  out  using  ﬁve  loci.
Results:  Eighty  isolates  with  a nalidixic  acid MIC of <32  mg/L  (NALS) and  a ciproﬂoxacin  MIC  of  >0.064  mg/L
CIPI (ciproﬂoxacin  reduced  susceptibility)  were  found.  In  36 NALS CIPI isolates  two  distinct  genotypes
were  identiﬁed  when  compared  with  16  susceptible  controls:  Group  B (n =  34),  mutation  in  gyrB  at  codon
464,  NAL MIC  of  3–12  mg/L  and  CIP  MIC of 0.064–0.5  mg/L.;  and  Group  C,  mutation  in  gyrA  at  codon  83
(n  =  2) NAL  MIC  of 16  mg/L  and  CIP  MIC  of  0.25–0.38  mg/L.  Group  B isolates  were  found  in different  strain
backgrounds  as  deﬁned  by  MLVA.
Conclusion:  The  use  of  nalidixic  acid to screen  for reduced  susceptibility  to  ﬂuoroquinolones  in  S.  Typhi
misses  CIPI-NALS isolates,  an  established  phenotype  in  India.
©  2015  Published  by Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC BY-NC-ND  license. Introduction
Typhoid fever, caused by Salmonella enterica serovar Typhi (S.
yphi), remains a global public health problem centred in devel-
ping countries [1]. The emergence of multi-drug resistant (MDR)
. Typhi, with resistance to all ﬁrst line drugs: (chloramphenicol,
o-trimoxazole and ampicillin) led to the ﬂuoroquinolones becom-
ng the treatment of choice for enteric fever [2]. There is a clear
elationship between increasing ﬂuoroquinolone MIC  and outcome
uring ﬂuoroquinolone treatment of typhoid fever. Therefore for
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214-7535/© 2015 Published by Elsevier GmbH. This is an open access article under the C(http://creativecommons.org/licenses/by-nc-nd/4.0/).
clinical management, any increase in ﬂuoroquinolone MIC needs
to be detected [3]. No zone around a nalidixic acid 30 g disc has
been used as a screening test for isolates with a clinically rele-
vant ciproﬂoxacin resistance; MIC  of ≥0.125 mg/L with a sensitivity
of 92.9% (248/267); and a speciﬁcity of 98.4% (540/549) [4]. The
most common mutation associated with reduced susceptibility to
ﬂuoroquinolones in S. Typhi is in the quinolone resistance deter-
mining region of the GyrA sub-unit of DNA gyrase. This mutation,
at amino acid 83, also confers resistance to nalidixic acid (NALR)
and so nalidixic acid can be a marker for ﬂuoroquinolone resis-
tance where this mutation is the sole cause of resistance. Strains
of S. Typhi with decreased susceptibility to ﬂuoroquinolones (e.g.
ciproﬂoxacin (CIPI) MIC  > 0.064 mg/L are now very common in India
[3]. The reports of alternative mechanisms of ﬂuoroquinolone resis-
tance are increasing [5,6]. In response to this the CLSI has redeﬁned
the breakpoints for ciproﬂoxacin as ≤0.064 mg/L and ≥1 mg/L and
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1
Primer sequences of plasmid mediated resistance (PMQR) genes: qnrA, qnrB, qnrS,
aac(6′)-Ib-cr and qepA.
S. No. Primer of PMQR genes Amplicon size
1. qnrA FP: 5′-ATT TCT CAC GCC AGG ATT TG-3′
RP: 5′-GAT CGG CAA AGG TTA GGT CA-3′
516 bp
2.  qnrB FP: 5′-GAT CGT GAA AGC CAG AAA GG-3′
RP: 5′-ACG ATG CCT GGT AGT TGT CC-3′
469 bp
3.  qnrS FP: 5′-ACG ACA TTC GTC AAC TGC AA-3′
RP: 5′-TAA ATT GGC ACC CTG TAG GC-3′
417 bp
4. aac(6′)-Ib-cr FP: 5′-TTG CGA TGC TCT ATG AGT GGC
TA-3′
RP: 5′-CTC GAA TGC CTG GCG TGT TT-3′
489 bp
5.  qepA FP: 5′-GCA GGT CCA GCA GCG GGT AG-3′ 1100 bp
F
(R. Gupta et al. / Biomolecular Detec
31 mm and ≤20 mm for susceptibility and resistance using MIC
nd disc diffusion [7], and strains that are >0.064 mg/L and <1 mg/L
s intermediate for Salmonella enterica. Many laboratories in India
owever continue to test nalidixic acid as a marker for decreased
usceptibility to ﬂuoroquinolones (CIPI) and so a formal report on
he utility of the nalidixic acid screening test in India is of great
mportance to guide clinical management. Furthermore there is
onﬂicting evidence on the role of ﬂuoroquinolones mutations in
linical isolates; two mutations in gyrA and/or gyrB can be associ-
ted with full resistance to ﬂuoroquinolones (MIC ≥ 4 mg/L) [8] but
enetic manipulation of isogenic mutants shows that this is not the
ull story – other mutations must also be present [9]. It is therefore
mportant to characterize circulating strain.
The Indian sub-continent reports more typhoid fever than any
ther world region and so monitoring of antibiotic resistance in S.
yphi in India can be used to detect any trend towards increas-
ng ciproﬂoxacin resistance. Our centre is one of the busiest in
ndia and surveillance of ciproﬂoxacin resistance has been car-
ied out since 2001. In a previous study from 2003 the majority
282/285) of isolates with CIPI exhibited the classical quinolone
esistance phenotype, NALR-CIPI and three isolates with NALS-CIPI
CIP-MIC 0.125 mg/L) were observed [10]. Here we present data on
he genetic and phenotypic characterization of CIPI isolates of S.
yphi from 2004 to 2011.
. Methods
All isolates were from patients admitted to the Safdarjung Hos-
ital during 2004–2011 and were from blood or stool cultures,
eduplication was carried out as far as possible using the clinical
ata available retrospectively. The Minimum Inhibitory Concentra-
ion (MIC) for nalidixic acid and ciproﬂoxacin against 891 S. Typhi
as determined by E-test (AB Biodisk, Solna, Sweden). Results were
nterpreted by two microbiologists and discrepant results were
epeated. Susceptibilities to nalidixic acid (30 g), ciproﬂoxacin
5 g) chloramphenicol (30 g), co-trimoxazole (25 g) and ampi-
illin (10 g) were determined by disc diffusion (DD) test according
o CLSI guidelines [7]. The breakpoints used for CIPI were
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ig. 1. The relative numbers of isolates of Salmonella Typhi at Safdarjung hospital. (A) N
MIC  ≤ 16 mg/L). NALR = nalidixic acid resistance (MIC ≥ 32 mg/L). CIPI = decreased ciproﬂoRP: 5′-CTT CCT GCC CGA GTA TCG TG-3′
0.064–1.0 mg/L and 21–30 mm for MIC  and DD respectively. MDR
was deﬁned as resistance to chloramphenicol, co-trimoxazole, and
ampicillin. The data was analyzed using WHONET 5.6. software.
From the NALS S. Typhi (MIC < 32 mg/L) 52 strains were selected
to represent all years of isolation and all antibiograms to charac-
terize the mechanism of FQ resistance. PCR was  used to amplify
the QRDRs of gyrA, gyrB, parC and parE genes [3]. Denaturing
high-pressure liquid chromatography (DHPLC: Wave Nucleic Acid
Fragment Analysis System; Transgenomic Inc.) was  used to study
mutations [11]. Mutations in the genes studied were identiﬁed
by comparison with DNA sequences from S. Typhi strains Ty2
(GenBank accession no. AE014613). Screening for the plasmid
determinants (qnrA,B,S; aac(6′)-Ib-cr and qepA) was carried out by
PCR (primers in Table 1).
Multi-locus variable number tandem repeat (VNTR) analysis
(MLVA) was  carried out to assess genetic relatedness using ﬁve
VNTR loci (TR1,TR2, TR4699, Sal02 and Sal16) [12]. Primers were
tagged with 6′FAM (blue) ﬂuorescent dye. Fragment length analysis
was done by capillary electrophoresis (ABI3130 Genetic analyzer,
Applied Biosystems). Fragment sizes were binned into alleles. Copy
number was  conﬁrmed by sequencing. A cluster dendogram was
constructed using R-software.
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enes; (B) a mutation in gyrB only; and (C) a mutation in gyrA only.
. Results and discussion
Among 891 S. Typhi isolates the numbers of each antibacterial
henotype isolated were as follows: of wild type (NALS-
IPS) 46 (5.2%), classical ﬂuoroquinolone decreased susceptibility
NALR-CIPI) 675 (75.8%), non-classical ﬂuoroquinolone decreased
usceptibility (NALS-CIPI) 80 (9%) and ﬂuoroquinolone resistance
0 (10%).
The proportion of NALR increased from 76.1% in 2004 to 97.0% in
011. Of interest is that among the NALS-isolates CIPI was  isolated
very year although the number varied (Fig. 1). In 2011 only 1/104
solates was fully susceptible to ciproﬂoxacin and nalidixic acid.
he NALS-CIPI isolates appear to be established within the popula-
ion. In order to assess the reasons for this stability we  decided to
nvestigate the genetic variation present within the population of
solates with the NALS-CIPI phenotype.nd zone size diameter, for 52 S. Typhi isolates with (A) no mutation in topoisomerase
No plasmid-encoded determinants were detected. No muta-
tions were observed in the QRDR of parC and parE. Mutations were
found in the QRDR of gyrA and gyrB. Results are shown in Table 2.
From the mutations detected we split all isolates into three groups.
Group A (n = 16): isolates with wild type gyrA and gyrB gene; Group
B (n = 34): gyrB mutation only; and Group C (n = 2) gyrA mutation
only. Scatter plots correlating the zone diameters and MIC  of CIP
vs NAL and CIP MIC  vs CIP zone diameters of these isolates are
shown in Fig. 2. Although there is some heterogeneity in this group
of 52 isolates it is clear that each group: A, B and C, could be dis-
tinctly identiﬁed based on the MIC  data for CIP and NAL (Table 2).
It is also clear that the mutations on gyrB (Group B) are a common
cause of the NALS-CIPI phenotype in S. Typhi in India. Group B iso-
lates (mutation in gyrB) were distinct, with NAL (3–12 mg/L) and
CIP (0.064–0.5 mg/L) MIC  being 3- and 15-fold higher respectively
than the wild type group A isolates but where difﬁcult to identify
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Table  2
Characteristics of the 52 Salmonella enterica serovar Typhi isolates belonging to Groups A, B and C, India 2004–2011.
Group No. of isolates NAL MIC  (g/ml) CIP MIC  (g/ml) QRDR mutation
MIC50 MIC90 GM MIC range MIC50 MIC90 GM MIC  range
A 16 2 3 2.06 1.5–3 0.012 0.016 0.012 0.006–0.023 No mutation
B  34a 6 8 6.44 3–12 0.125 0.19 0.13 0.064–0.5 gyrB 464
Ser→Tyr (n = 2)
Ser→Phe (n = 31)
Ser→Thre (n = 1)
C  2 16 16 16 16 0.25 0.38 0.38 0.25–0.38 gyrA 83
Ser→Tyro
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cAL, nalidixic acid; CIP, ciproﬂoxacin; GM,  geometric mean; QRDR, quinolone resis
a 13 isolates were additionally resistant to chloramphenicol, co-trimoxazole and
y a single phenotypic test; only 16/34 group B isolates were CIPI
oth by disc diffusion and MIC. Thus using the revised CLSI break-
oints the group B isolates would be very difﬁcult to classify: the
iproﬂoxacin zone diameter breakpoint and MICs for this group
f isolates cut across the deﬁned breakpoints. This is in agreement
ith reports from France (n = 12) [13] and UK (n = 8) where reported
IP-MIC range among S. Typhi NALS-CIPI with gyrB mutation were
.032–0.19 mg/L and 0.03–0.05 mg/L respectively [14]. The pre-
ominant gyrB mutation among isolates of Indian origin in these
tudies was Ser-464→Phe (accession no. KF993966). Our ﬁndings
orroborate this. The gyrB mutations at Asp 466, Leu 465 and Glu
68 reported earlier [6,13] were not observed in our study. Other
utations observed among our isolates were Ser-464→Tyro (n = 2)
accession no. KF993965) and a novel mutation not reported so far
as observed at Ser-464→Thre (n = 1) (accession no. KF993964).
One explanation for the phenotypic variation could be strain
ackground and their genetic relatedness was assessed by MLVA.
mong group B isolates tested, 17 distinct VNTR proﬁles were
bserved (data not shown). This suggests that the selective
dvantage of the resistance phenotype associated with gyrB
er-464→Phe is not associated with a biological cost. Were com-
ensatory mutations necessary the primary mutation would be
resent in a limited portion of the population–this is not the case,
yrB Ser-464→Phe has become ﬁxed in several branches of the pop-
lation. There were also two isolates which were MDR  as well as
ALSCIPI with a mutation at gyrB Ser-464→Phe and two NALS-CIPI
solates with different MDR  phenotype also showed an identical
NTR proﬁle suggesting that there was no linkage between the
DR  phenotype and gyrB Ser-464→Phe. This data means that los-
ng the mutations, and by association the CIPI phenotype, from the
opulation by reducing selection from the use of ﬂuoroquinolones
s very unlikely.
Two isolates Group C, selected as NALS CIPI (MIC 16 mg/L and
one diameter 18 and 19 mm for nalidixic acid) had gyrA mutation
Ser-83→Tyr) which would normally encode resistance to nalidixic
cid, these strains must have an unusual background which poten-
iated the action of nalidixic acid but not the ﬂuoroquinolones. We
id not have the resource to investigate these interesting strains
urther.
. Conclusions
It is important to know the clinical signiﬁcance of NALS-CIPI
mong S. Typhi. The impact of the NALS-CIPI on ﬂuoroquinolone
reatment in typhoid fever is unknown as there are no studies that
ocument outcome of this infection following treatment. Even in
ur study, patients with infection due to these strains could not be
ollowed as most of them presented in the outpatient department.
owever, the CIP MIC  is likely to be the most important deter-
inant of clinical response to therapy, irrespective of resistance
echanism and therefore CIPI must be considered as likely to fail
iproﬂoxacin therapy. Furthermore the emergence of NALS-CIPI indetermining region of the gyrA, gyrB, parC and parE genes.
illin.
several different background strains for S. Typhi, as evidenced by
the MLVA data, suggests that these CIPI mutants are biologically
ﬁt. We therefore have signiﬁcant concern that under-reporting
of CIPI by a failure to detect CIPI-NALS isolates (by conventional
NAL resistance) may  facilitate the subsequent emergence of high-
level FQ resistance. Our results show that screening with nalidixic
acid only will not detect 14/34 and 5/34 of the CIPI-NALS iso-
lates supporting the CLSI guidelines to use CIP testing to detect
CIPI Salmonella.  Alternative screening tests need to be explored to
identify these isolates for optimal treatment. Co-existence of the
MDR  phenotype in 38.2% of CIPI-NALS may further restrict ther-
apeutic options. There has been a rapid evolution of NALR-CIPI
that has been maintained through selective pressure and these
strains are now endemic in India subcontinent. It is thus important
to study the spread of NALS-CIPI strains. These isolates repre-
sented 11.6% (49/421) of the S. Typhi isolated in England, Scotland,
and Wales (1999–2003) and 4.6% (36/770) of S. Typhi isolates
in the United States (1999–2006). In France among 685 S. Typhi
(1997–2009) the incidence of these isolates was  rare (1.0%). In our
study (2004–2011) overall prevalence of these isolates was  9.0%.
Among the NAL susceptible population during 2004–2011 the ratio
of isolates CIPI-NALS to wild type QRDR shifted from 1:1.3 to 2:1,
but their isolation has decreased from 10.3 to 1.9%. Although the
overall prevalence of these strains is declining, they have arisen and
spread on more than one occasion and so will likely reemerge in
the future.
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